Table 1A.

Studies included in review.

Study	Dallocchio, et al⁶								Gerloni et al⁵
Publish yr	2010								2008
Study design	Observational								Observational
Sex	M	F	F	F	M	F	F	F	NS	NS	NS	NS	NS
Age at IBD onset, yrs	14.8	17.8	13.5	12.6	14	14.7	13.5	17	NS	NS	NS	NS	NS
Underlying disease	Oligo JIA	ERA JIA	Poly JIA	Oligo JIA	ERA JIA	Oligo JIA	Oligo JIA	Systemic JIA	JIA NOS	JIA NOS	JIA NOS	JIA NOS	JIA NOS
Age at rheumatic disease onset, yrs	3	10.3	3.5	7.5	13	11.5	4	6	NS	NS	NS	NS	NS
Duration of ETN treatment, yrs	0.6	1	6.5	4.1	1	0.8	2	2	NS	NS	NS	NS	NS
Time from disease diagnosis to ETN start, yrs	11.2	6.5	3.5	1	0	2.5	7.5	9	NS	NS	NS	NS	NS
Time from ETN to IBD, yrs	0.6	1	6.5	4.1	1	0.8	2	2	NS	NS	NS	NS	NS
CD/UC	CD	CD	CD	ID	ID	ID	CD	CD	CD	CD	ID	ID	ID
Biopsy	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	N	N	Y
Concomitant treatment	NSAID	NSAID, MTX, SSZ, PSL	NSAID, PSL	PSL, NSAID, MTX	NSAID, SSZ, MTX	NSAID, MTX	NSAID, MTX	NSAID	NS	NS	NS	NS	NS
Decrease in IBD symptoms	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS
IBD treatment after	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS
IBD progression: penetrating, stricturing, inflammatory	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS

IBD: inflammatory bowel disease; ETN: etanercept; CD: Crohn disease; UC: ulcerative colitis; NS: not specified; oligo: oligoarticular; JIA: juvenile idiopathic arthritis; ERA: enthesitis-related arthritis; poly: polyarticular; NOS: not otherwise specified; ID: undifferentiated IBD; NSAID: nonsteroidal antiinflammatory drugs; MTX: methotrexate; SSZ: sulfasalazine; PSL: prednisone.